Sandu [SANDUPHQ] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison

Sandu Pharmaceuticals, Inc.

BSE
Loading...

Sun Pharmaceutical Industries Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Sandu Pharmaceuticals, Inc. wins in 9 metrics, Sun Pharmaceutical Industries Ltd. wins in 11 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Sandu Pharmaceuticals, Inc. Sun Pharmaceutical Industries Ltd. Better
P/E Ratio (TTM) 20.68 36.73 Sandu Pharmaceuticals, Inc.
Price-to-Book Ratio 1.00 5.15 Sandu Pharmaceuticals, Inc.
Debt-to-Equity Ratio 1.06 6.68 Sandu Pharmaceuticals, Inc.
PEG Ratio 0.27 3.59 Sandu Pharmaceuticals, Inc.
EV/EBITDA 14.48 23.61 Sandu Pharmaceuticals, Inc.
Profit Margin (TTM) 3.06% 19.21% Sun Pharmaceutical Industries Ltd.
Operating Margin (TTM) 4.66% 26.17% Sun Pharmaceutical Industries Ltd.
EBITDA Margin (TTM) 4.66% 26.17% Sun Pharmaceutical Industries Ltd.
Return on Equity 3.69% 15.08% Sun Pharmaceutical Industries Ltd.
Return on Assets (TTM) 2.78% 11.87% Sun Pharmaceutical Industries Ltd.
Free Cash Flow (TTM) $104,000 $119.44B Sun Pharmaceutical Industries Ltd.
Dividend Yield 1.61% 0.97% Sandu Pharmaceuticals, Inc.
1-Year Return -20.14% 7.25% Sun Pharmaceutical Industries Ltd.
Price-to-Sales Ratio (TTM) 0.63 7.05 Sandu Pharmaceuticals, Inc.
Enterprise Value $388.60M $3,783.37B Sun Pharmaceutical Industries Ltd.
EV/Revenue Ratio 0.58 6.66 Sandu Pharmaceuticals, Inc.
Gross Profit Margin (TTM) 57.96% 80.96% Sun Pharmaceutical Industries Ltd.
Revenue per Share (TTM) $69 $237 Sun Pharmaceutical Industries Ltd.
Earnings per Share (Diluted) $2.11 $45.46 Sun Pharmaceutical Industries Ltd.
Beta (Stock Volatility) 0.07 0.11 Sandu Pharmaceuticals, Inc.

Sandu Pharmaceuticals, Inc. vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis

Loading Price Chart...

SANDUPHQ
SUNPHARMA

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Sandu Pharmaceuticals, Inc.-1.05%-2.49%0.12%20.90%8.96%13.59%
Sun Pharmaceutical Industries Ltd.-0.08%-2.77%-1.84%2.13%-0.53%4.00%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Sandu Pharmaceuticals, Inc.-20.14%-27.30%3.19%44.33%226.85%236.00%
Sun Pharmaceutical Industries Ltd.7.25%79.99%166.96%144.01%669.48%2,278.32%

Performance & Financial Health Analysis: Sandu Pharmaceuticals, Inc. vs Sun Pharmaceutical Industries Ltd.

MetricSANDUPHQSUNPHARMA
Market Information
Market Cap i₹421.61M₹3.88T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i7,6993,903,142
90 Day Avg. Volume i5,4313,253,866
Last Close₹42.59₹1,788.50
52 Week Range₹30.00 - ₹58.28₹1,548.00 - ₹1,916.60
% from 52W High-26.92%-6.68%
All-Time High₹86.00 (Apr 25, 2022)₹1,960.35 (Sep 30, 2024)
% from All-Time High-50.48%-8.77%
Growth Metrics
Quarterly Revenue Growth0.02%0.14%
Quarterly Earnings Growth0.76%0.16%
Financial Health
Profit Margin (TTM) i0.03%0.19%
Operating Margin (TTM) i0.05%0.26%
Return on Equity (TTM) i0.04%0.15%
Debt to Equity (MRQ) i1.066.68
Cash & Liquidity
Book Value per Share (MRQ)₹43.50₹324.46
Cash per Share (MRQ)₹3.85₹115.87
Operating Cash Flow (TTM) i₹5.35M₹110.84B
Levered Free Cash Flow (TTM) i₹15.52M₹109.29B
Dividends
Last 12-Month Dividend Yield i1.61%0.97%
Last 12-Month Dividend i₹0.80₹16.50

Valuation & Enterprise Metrics Analysis: Sandu Pharmaceuticals, Inc. vs Sun Pharmaceutical Industries Ltd.

MetricSANDUPHQ (Apr 24, 2026)SUNPHARMA (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i20.6836.73
Forward P/E iN/A29.48
PEG Ratio i0.273.59
Price to Sales (TTM) i0.637.05
Price to Book (MRQ) i1.005.15
Market Capitalization
Market Capitalization i₹421.61M₹3.88T
Enterprise Value i₹388.60M₹3.78T
Enterprise Value Metrics
Enterprise to Revenue i0.586.66
Enterprise to EBITDA i14.4823.61
Risk & Other Metrics
Beta i0.070.11
Book Value per Share (MRQ) i₹43.50₹324.46

Financial Statements Comparison: Sandu Pharmaceuticals, Inc. vs Sun Pharmaceutical Industries Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSANDUPHQ (2025)SUNPHARMA (2025)
Revenue/Sales i671.92M520.41B
Cost of Goods Sold i332.04M121.98B
COGS % of Revenue i49.4%23.4%
Gross Profit i339.88M398.44B
Gross Margin i50.6%76.6%
Research & Development i2.33MN/A
Operating Income (EBIT) i20.94M125.81B
Operating Margin i3.1%24.2%
EBITDA i29.26M167.25B
EBITDA Margin i4.4%32.1%
Pre-Tax Income i21.59M137.52B
Pre-Tax Income % of Revenue i3.2%26.4%
Income Tax i6.07M27.72B
Income Tax % of Revenue i0.9%5.3%
Net Income (Profit) i15.52M109.65B
Profit Margin i2.3%21.1%

Balance Sheet & Liquidity Metrics

MetricSANDUPHQ (2025)SUNPHARMA (2025)
Cash & Equivalents i13.04M102.69B
Total Current Assets i262.99M526.24B
Total Current Assets % of Revenue i39.1%101.1%
Total Current Liabilities i120.86M181.94B
Total Current Liabilities % of Revenue i18.0%35.0%
Long-Term Debt i4.19M3.58B
Long-Term Debt % of Revenue i0.6%0.7%
Total Shareholders Equity i420.17M724.86B
Retained Earnings i95.24M578.62B
Retained Earnings % of Revenue i14.2%111.2%
Property, Plant & Equipment i7.46M100.36B

Cash Flow Statement Comparison

MetricSANDUPHQ (2025)SUNPHARMA (2025)
Operating Cash Flow i5.35M110.84B
Operating Cash Flow % of Revenue i0.8%21.3%
Capital Expenditures i-9.38M-20.68B
Free Cash Flow i104,000119.44B
FCF Margin i0.0%23.0%
Debt Repayment iN/A-43.44B
Common Stock Repurchase iN/A-29.00B

Short Interest & Institutional Ownership Analysis

MetricSANDUPHQSUNPHARMA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i9.66M2.40B
Float Shares i3.21M1.07B
% Held by Insiders i65.51%55.62%
% Held by Institutions i0.00%28.69%
% Held by Public i34.49%15.69%

Dividend Analysis & Yield Comparison: Sandu Pharmaceuticals, Inc. vs Sun Pharmaceutical Industries Ltd.

MetricSANDUPHQSUNPHARMA
Last 12-Month Dividend i₹0.80₹16.50
Last 12-Month Dividend Yield i1.61%0.97%
3-Year Avg Annual Dividend i₹1.02₹17.33
3-Year Avg Dividend Yield i1.12%0.51%
3-Year Total Dividends i₹3.05₹52.00
Ex-Dividend DateSep 19, 2024Feb 05, 2026